Urologic Oncology-seminars and Original Investigations最新文献

{"title":"Corrigendum to \"Clinician interest in clinical decision support for PSA-based prostate cancer screening\" [Urol Oncol: Semin Original Investigat. 41(3) March 2023, 145.e17-145.e23].","authors":"Jonathan Harper, Trevor C Hunt, Mouneeb Choudry, Ashley L Kapron, Kathleen A Cooney, Christopher Martin, Jacob Ambrose, Brock O'Neil","doi":"10.1016/j.urolonc.2025.03.010","DOIUrl":"https://doi.org/10.1016/j.urolonc.2025.03.010","url":null,"abstract":"","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143744088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to 'Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide'[Urol Oncol: Semin Original Investigat 41(3) (2023) 253.e1-253.e9].","authors":"Benjamin Lowentritt, Dominic Pilon, Ibrahim Khilfeh, Carmine Rossi, Erik Muser, Frederic Kinkead, Dexter Waters, Lorie Ellis, Patrick Lefebvre, Gordon Brown","doi":"10.1016/j.urolonc.2025.03.011","DOIUrl":"https://doi.org/10.1016/j.urolonc.2025.03.011","url":null,"abstract":"","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143744090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The fragility index of randomized controlled trials in advanced/metastatic renal cell cancer.","authors":"Yingwei Bi, Haotian Wei, Qifeng Ma, Rui Wang, Jiacheng Jin, Kexin Qu, Yuxin Liu, Ziwei Zhai, Liang Zhu, Jianbo Wang","doi":"10.1016/j.urolonc.2025.03.003","DOIUrl":"https://doi.org/10.1016/j.urolonc.2025.03.003","url":null,"abstract":"<p><strong>Purpose: </strong>The fragility index (FI) has been applied as a supplement to the noncomprehensive P-values to assess the robustness of randomized controlled trials (RCTs). The objective of this study is to evaluate the statistical robustness of RCTs of advanced/metastatic renal cell cancer (a/mRCC) using the FI.</p><p><strong>Materials and methods: </strong>RCTs related to a/mRCC published in the 4 highest-impact general medical journals and the 25 highest-impact urological journals between January 1, 2000, and December 31, 2023, were identified from PubMed database. The FI was calculated by using Fisher's exact test. Spearman's correlation analysis was conducted to assess potential correlates regarding FI.</p><p><strong>Results: </strong>16 eligible RCTs were screened with a median total sample size of 654.5 (IQR, 461-847) and a median patients lost to follow-up of 14 (IQR, 3-23). The median FI was 12.5 (IQR, 8.5-27), suggesting that a switch in outcomes in only 13 patients would have reversed the significance of the trials. The number of patients lost to follow-up exceeded or equaled to the FI in 7 (44%) RCTs. P-values were negatively associated with the FI, while the number of patients lost to follow-up and patients enrolled were not statistically significant.</p><p><strong>Conclusion: </strong>Not all RCTs associated with a/mRCC are as statistically robust as previously considered and should therefore be construed carefully. We suggest that additional reporting of FI in urological RCTs as a supplement to the P-value to assist readers in concluding reliably by considering the fragility of the outcomes.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143744093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of glucocorticoid treatment and clinical prognostic factors for outcome in patients with advanced urothelial cancer treated with pembrolizumab.","authors":"Gustav Hjorthén, Fernanda Costa Svedman, Karin Holmsten, Anders Ullén","doi":"10.1016/j.urolonc.2025.02.017","DOIUrl":"https://doi.org/10.1016/j.urolonc.2025.02.017","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors have become a cornerstone in treatment of metastatic urothelial cancer (mUC), but reliable prognostic and treatment predictive factors remain to be defined. Glucocorticoids (GC) are used to manage immune-related adverse events (irAE), and the potential impact on treatment outcome is still unclear.</p><p><strong>Objectives: </strong>The aim of this study was to explore the impact of GC treatment alongside clinical parameters on outcome in pembrolizumab-treated mUC patients.</p><p><strong>Materials and method: </strong>A single-center retrospective real-world study was performed including all consecutive mUC patients in first- or second-line treated with pembrolizumab. Multivariate analyses were used to explore the impact of baseline characteristics on response-rate and overall survival (OS). Landmark analysis was applied to adjust for immortal time bias in survival analyzes.</p><p><strong>Results: </strong>107 patients were included. Patients developing irAE requiring GC treatment had superior OS compared to those who did not (17.6 months vs. 8.8 months, P = 0.003). Ongoing treatment with GC prior to the initiation of pembrolizumab, ECOG PS >1 and liver metastases were independently associated with worse OS. We constructed a risk-score model where the number of zero, 1, 2 or 3 risk factors correlated to an OS of 11.7 months, 3.8 months, and 3.0 months respectively (P < 0.001).</p><p><strong>Conclusion: </strong>The development of irAE requiring GC treatment was associated with favorable survial outcomes. Ongoing GC treatment before the commencement of pembrolizumab, ECOG PS >1, and presence of liver metastases were associated with worse OS. We propose a risk-score model to assist clinicians in selecting patients for treatment with pembrolizumab.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143721345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant chemotherapy prior to radical nephroureterectomy: Survival outcomes and recurrence patterns by pathologic node status.","authors":"Farshad Sheybaee Moghaddam, Rashid K Sayyid, Alireza Ghoreifi, Antonio Franco, Zhenjie Wu, Linhui Wang, Alessandro Antonelli, Francesco Ditonno, Firas Abdollah, Marco Finati, Giuseppe Simone, Gabriele Tuderti, Emma Helstrom, Andres F Correa, Ottavio De Cobelli, Matteo Ferro, Francesco Porpiglia, Daniele Amparore, Antonio Tufano, Sisto Perdonà, Stephan Brönimann, Nirmish Singla, Margaret F Meagher, Ithaar H Derweesh, Dinno F Mendiola, Mark L Gonzalgo, Reuben Ben-David, Reza Mehrazin, Sol C Moon, Soroush Rais-Bahrami, Courtney Yong, Chandru P Sundaram, Raj Bhanvadia, Vitaly Margulis, Riccardo Autorino, Hooman Djaladat","doi":"10.1016/j.urolonc.2025.03.001","DOIUrl":"https://doi.org/10.1016/j.urolonc.2025.03.001","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate survival outcomes and recurrence patterns by pathologic nodal status in upper tract urothelial carcinoma (UTUC) patients receiving neoadjuvant chemotherapy (NAC) prior to radical nephroureterectomy (RNU) and lymph node dissection (LND).</p><p><strong>Materials and methods: </strong>Using the international ROBUUST 2.0 database, a retrospective analysis of UTUC patients who underwent robotic/laparoscopic RNU+LND±NAC was performed. Patients were stratified by NAC and pathologic nodal status into pN0, ypN0, pN+, and ypN+ subgroups. Overall (OS), metastasis-free (MFS), and urothelial recurrence-free survivals (RFS) were compared using Kaplan-Meier curves and multivariable Cox regression modeling.</p><p><strong>Results: </strong>The cohort included 883 patients (15% received NAC). 212 (24%) patients had (y)pN+ disease. Median follow-up was 19 months. Compared to pN+ patients, ypN+ patients had significantly worse 1- (64% vs. 72%), 3- (40% vs. 54%), and 5-year (20% vs. 31%) OS rates. Node-negative patients had similar OS, irrespective of NAC treatment (1-year: 94%; 3-year: 77%-82%). At 1 year, all ypN+ patients had metastases, while 13% of pN+ patients remained metastasis-free. Among ypN+ patients, 89% experienced nodal/regional or distant metastases as the site of initial recurrence, compared to 39% of pN+ patients. Initial nodal/regional or distant metastases occurred in 42% and 18% of ypN0 and pN0 patients, respectively.</p><p><strong>Conclusion: </strong>ypN+ patients have worse survival compared to pN+ patients. Recurrence patterns differ by nodal and NAC status, with ypN+ patients having a significantly higher incidence of nodal/regional or distant metastases as the initial site of recurrence. These survival outcomes and recurrence patterns differences may have important surveillance and treatment implications.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143711026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of RNA sequencing in urologic malignancies: Advances and challenges.","authors":"Khaleel I Al-Obaidy, Liang Cheng","doi":"10.1016/j.urolonc.2025.03.007","DOIUrl":"https://doi.org/10.1016/j.urolonc.2025.03.007","url":null,"abstract":"<p><p>RNA sequencing became a key tool in identifying the differences between cells and their functions, aiding in the recognition of the functional elements disrupted during the disease process. In urologic malignancies, many studies aiming to provide comprehensive molecular classifications through the assessment of RNA expression or fusion analysis have been published. The distinctive presence of these molecular alterations related to cancer development, growth, and survival and the discoveries of these breakthrough studies provide insight into the development of personalized management and aid in the identification of new therapeutic targets.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143693025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does inclusion of neighborhood variables improve clinical risk prediction for advanced prostate cancer in Black and White men?","authors":"Erin K Tagai, Elizabeth A Handorf, Kristen A Sorice, Carolyn Y Fang, Mengying Deng, Mary B Daly, Adam C Reese, Kevin A Henry, Camille Ragin, Shannon M Lynch","doi":"10.1016/j.urolonc.2025.02.021","DOIUrl":"https://doi.org/10.1016/j.urolonc.2025.02.021","url":null,"abstract":"<p><strong>Introduction: </strong>Black men are diagnosed with high-grade prostate cancer (PCa; Gleason sum ≥7) at greater rates than White men. This persistent disparity has led to mortality rates among Black men that are twice the rate of White men. Risk prediction tools can aid clinical decision making for PCa screening, biopsy, and treatment. However, research has not integrated neighborhood-level risk factors that are associated with rates of high-grade PCa. This study sought to determine whether inclusion of neighborhood-level variables can improve prediction of high-grade PCa over the existing Prostate Cancer Prevention Trial (PCPT) calculator.</p><p><strong>Methods: </strong>Existing PCa cases from 2005 to 2017 were ascertained from urology, radiation, and medical oncology clinics at Fox Chase Cancer Center/Temple University Health System (FCCC/TUHS). Existing databases from patient medical records, biosamples, pathology, and neighborhood data from the U.S. census were linked via geocodes. Informed by prior studies that selected social environmental variables, a series of logistic regression models were completed to predict the probability of high-grade PCa on prespecified sets of variables from the PCPT.</p><p><strong>Results: </strong>Our best fitting, multilevel model included PCPT variables (i.e., PSA, digital rectal exam, age, race, prior biopsy, family history) as well as insurance status, neighborhood-level poverty, residence in a high risk PCa cluster, and % of Employed Men in Protective Service Occupations. However, the AUC for this model (0.673) was only marginally improved from the initial model of only PCPT variables (0.671). Further, in separate analyses by race (White, Black) the % of Employed Men in Protective Service Occupations was only significant among White men.</p><p><strong>Discussion: </strong>Study findings demonstrate the potential for neighborhood variables to enhance current risk prediction models and identify interaction effects revealing differences across subgroups, such as race. The lack of significant associations between neighborhood variables and Black men highlight the complexity of systemic racism and neighborhood-level variables on PCa outcomes.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143693035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic performance of high-resolution micro-ultrasound and conventional ultrasound in fusion biopsy for clinically significant prostate cancer detection.","authors":"Ghazal Khajir, Lindsey T Webb, Soum D Lokeshwar, Gabriela M Diaz, Taira Anderson, Ankur U Choksi, Julian Zhao, Michael S Leapman, Preston C Sprenkle, Joseph F Renzulli","doi":"10.1016/j.urolonc.2025.03.006","DOIUrl":"https://doi.org/10.1016/j.urolonc.2025.03.006","url":null,"abstract":"<p><strong>Background: </strong>The aim of this study was to evaluate the diagnostic outcomes of MRI-ultrasound fusion targeted biopsy in detecting clinically significant prostate cancer (csPCa) using either microUS technology or conventional ultrasound.</p><p><strong>Methods: </strong>We identified a matched sample of 899 patients who underwent biopsy at a single institution between January 2017 and January 2023. A paired group of 470 patients was included. The proportion of cancers detected (any cancer and grade group (GG) ≥ 2) was compared between MRI-microUS and MRI-conventional US fusion biopsy groups.</p><p><strong>Results: </strong>The overall incidence of GG ≥ 2 cancer was similar between MRI-microUS and MRI-conventional US fusion biopsy groups (53.6% vs. 55.3%, P > 0.05). In patients undergoing MRI-microUS fusion biopsy, detection of any cancer in SB was greater than TB (69.2% vs. 57.1%, P < 0.001), while GG ≥ 2 detection was similar between SB and TB (44.9% vs. 40.5%, P = 0.06). Moreover, detection of any cancer and GG ≥ 2 using TB were lower in the MRI-microUS fusion biopsy group. On multivariable analysis, age, race, biopsy status, PSA density, and PI-RADS score were significantly associated with detection of GG ≥ 2.</p><p><strong>Conclusion: </strong>MicroUS-guided biopsy and conventional US-guided biopsy had similar rates of overall csPCa detection. Targeted biopsy using MRI-microUS fusion yielded lower overall and csPCa detection compared with MRI-conventional US fusion biopsy. MicroUS fusion biopsy is a reasonable alternative to conventional biopsy to detect csPCa.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143693031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between perioperative activity levels and discharge outcomes after radical cystectomy.","authors":"Ryan S Lee, Mazyar Zahir, Antoin Douglawi, Seyedeh Sanam Ladi-Seyedian, Chirag Doshi, Alireza Ghoreifi, Madeleine Burg, Azadeh Nazemi, Siamak Daneshmand","doi":"10.1016/j.urolonc.2025.03.005","DOIUrl":"https://doi.org/10.1016/j.urolonc.2025.03.005","url":null,"abstract":"<p><strong>Introduction: </strong>Early postoperative ambulation shortens the recovery of radical cystectomy (RC). This study aims to evaluate the potential associations between perioperative activity levels, measured by wearable fitness trackers (WFTs), and discharge outcomes after RC.</p><p><strong>Methods: </strong>In this prospective study, patients undergoing RC between 2017 and 2019 wore WFTs from a maximum of 2 weeks preoperatively, throughout their hospitalization, and up to 2 weeks after discharge. Activity levels were recorded as daily steps and calorie expenditure. Primary outcomes of interest were discharge disposition to a nursing facility and prolonged length of stay (LOS ≥ 5 days).</p><p><strong>Results: </strong>A total of 55 patients (80.0% male), with a median (IQR) age of 74 (65.0-79.5) years participated in the study, wearing the WFTs for a median of 18 (14.5-23) days. Twenty-seven (49%) patients had neobladders, and 11 (20.0%) were discharged to a nursing facility. The median LOS at the hospital was 4 (3.5-6) days. Patients with ileal conduit and those discharged to a nursing facility had significantly lower preoperative daily step counts compared to those who had neobladder and were discharged to home, respectively (both P < 0.05). Patients with prolonged LOS had lower daily calorie expenditure preoperatively (1,970 vs. 2,490, P < 0.001), and during hospitalization (1,850 vs. 2,070, P = 0.009).</p><p><strong>Conclusion: </strong>Lower preoperative calorie expenditure and step counts are associated with prolonged LOS and higher rates of discharge to nursing facilities. Larger studies are required to determine whether lower baseline activity can affect clinical outcomes.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143693313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Convalescence after radical orchiectomy: Detailing surgical recovery with a novel electronic patient reported outcome (ePRO) platform.","authors":"Samuel A Gold, Viranda H Jayalath, Rebecca Yu, Fady Baky, Nicole Liso, Brandon Williams, Amy L Tin, Sigrid Carlsson, Jennifer Cracchiolo, Andrew J Vickers, Joel Sheinfeld, Richard S Matulewicz","doi":"10.1016/j.urolonc.2025.02.018","DOIUrl":"https://doi.org/10.1016/j.urolonc.2025.02.018","url":null,"abstract":"<p><strong>Purpose: </strong>To assess implementation of an electronic patient reported outcomes platform, Recovery Tracker, which characterizes short term recovery following radical orchiectomy in patients with testicular cancer.</p><p><strong>Methods: </strong>Recovery Tracker was assigned based on procedure codes to patients undergoing radical orchiectomy at our institution. Patients were surveyed daily for the 10-day postoperative period in multiple symptom domains. To assess implementation outcomes, responders of at ≥1 survey were compared to nonresponders based on demographic and disease characteristics. Responses were described to ascertain recovery across domains. Clinically significant symptoms were identified based on reporting \"moderate\" or greater severity, or \"occasional\" or higher frequency answers.</p><p><strong>Results: </strong>From 06/2021 to 10/2023, 244 patients underwent orchiectomy. 236 (97%) were assigned a survey and 206 (87%) completed ≥1 survey. American Society of Anesthesiologists score of 3-4 (a measure of health comorbidities for which higher scores indicate worse overall health) was associated with worse response rates (P = 0.014). There were no other differences in survey response rates among demographic or disease factors, including clinical stage. There were no Clavien-Dindo Grade ≥2 30-day postoperative complications and 2 (0.8%) Grade 1 complications. Regarding symptomatology, only \"pain\" and \"limited activities due to pain\" were reported to be moderate/severe among most patients early in the postoperative period. After postoperative day 5, very few patients reported moderate or severe symptoms.</p><p><strong>Conclusions: </strong>Recovery Tracker was successfully assigned to and completed by nearly all patients undergoing radical orchiectomy. Convalescence data establishes clear recovery benchmarks to provide preoperative guidance on expected symptoms and identify potential abnormal postoperative courses for rapid intervention.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}